  This study introduces the HYPERSCINT research platform, the first
commercially available scintillation dosimetry platform capable of multi-point
dosimetry through the hyperspectral approach. Optic and dosimetric performances
of the system were investigated through comparison with another commercially
available solution, the Ocean Optics QE65Pro spectrometer. The optical
characterization was accomplished by measuring the linearity of the signal as a
function of integration time, photon detection efficiency and spectral
resolution for both systems. Dosimetric performances were then evaluated with a
3-point plastic scintillator detector (mPSD) in terms of signal to noise ratio
(SNR) and signal to background ratio (SBR) associated with each scintillator.
The latter were subsequently compared with those found in the literature for
the Exradin W1, a single-point plastic scintillator detector. Finally, various
beam measurements were realized with the HYPERSCINT platform to evaluate its
ability to perform clinical photon beam dosimetry. Both systems were found to
be comparable in terms of linearity of the signal as a function of the
intensity. Although the QE65Pro possesses a higher spectral resolution, the
detection efficency of the HYPERSCINT is up to 1000 time greater. Dosimetric
measurements shows that the latter also offers a better SNR and SBR, surpassing
even the SNR of the Exradin W1 single-point PSD. While the doses ranging from 1
cGy to 600 cGy were accurately measured within 2.1% of the predicted dose using
the HYPERSCINT platform coupled to the mPSD, the Ocean optics spectrometer
shows discrepencies up to 86% under 50cGy. Similarly, depth dose, full width at
half maximum region of the beam profile and output factors were all accurately
measured within 2.3% of the predicted dose using the HYPERSCINT platform and
exhibit an average difference of 0.5%, 1.6% and 0.6%, respectively.
